Bioptigen | Stephens

Who We Are

What We Do

We provide investment banking, research, sales and trading, asset and wealth management, public finance, insurance, private capital, and family office services.

About Us

We are a family-owned financial services firm that values client relationships, long-term stability, and supporting the communities where we live and work.

The Stephens Story

The idea of family defines our culture, because each of us knows that our reputation is on the line as if our own name was on the door.


Our reputation as a leading independent financial services firm is built on the stability of our longstanding and highly experienced senior executives.

Impact Initiatives

We are committed to corporate philanthropy; economic and financial literacy advocacy; and diversity, equity, and inclusion initiatives.

Our Brand Ambassadors

Stephens is proud to sponsor the PGA TOUR, LPGA Tour, and PGA TOUR Champions careers, as well as applaud the philanthropic endeavors, of our Brand Ambassadors.

Making Connections

We host many highly informative meetings each year with clients, industry decision makers, and thought leaders across the U.S. and in Europe.

Back to transactions
Financial Advisor


Value Not Disclosed 06/08/2015 Life Sciences & Medical Devices Complete
Public Companies
Show Tombstone

Transaction Details

  • On June 8, 2015, Bioptigen, Inc., (“Bioptigen” or “Company”) was acquired by Leica Microsystems, a subsidiary of Danaher Corporation (NYSE: DHR)
  • Bioptigen develops and manufactures innovative optical coherence tomography, or OCT, systems and software for clinical and research applications
  • The Company currently markets the FDA-cleared and CE-marked Envisu C2300 OCT device for handheld, pediatric, and perioperative applications, and sells advanced ophthalmic OCT imaging systems for preclinical research globally
  • The integration of Bioptigen’s OCT imaging into Leica Microsystems’ surgical microscopes will jointly leverage ophthalmic imaging technologies, address broader research and clinical markets, and more efficiently complete the next steps in integrating OCT imaging capabilities into the operating room
  • The terms of the acquisition were not disclosed
  • Stephens Inc. served as exclusive financial advisor to Bioptigen

About the company

Bioptigen, Inc.

Bioptigen, Inc. develops and manufactures Spectral Domain Optical Coherence Tomography (SDOCT) equipment and software, helping researchers explore ocular development and ocular disease. Deployed in top ophthalmic research and clinical institutions worldwide, Bioptigen SDOCT systems are supported by over 40 awarded patents. Bioptigen manufactures and sells SDOCT systems from the Company’s headquarters in Morrisville, North Carolina.

Leica Microsystems

Leica Microsystems develops and manufactures microscopes and scientific instruments for the analysis of microstructures and nanostructures. It is a market leader in compound and stereo microscopy, digital microscopy, confocal laser scanning microscopy with related imaging systems, electron microscopy sample preparation, and surgical microscopes. The Company has 7 major plants and product development sites around the world. The Company is represented in over 100 countries, has sales and service organizations in 20 countries, and an international network of distribution partners. Its headquarters are located in Wetzlar, Germany.

Danaher Corporation

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Company’s research and development, manufacturing, sales, distribution, service and administrative facilities are located in more than 50 countries. Danaher’s business consists of five segments: Test & Measurement; Environmental; Life Sciences & Diagnostics; Dental; and Industrial Technologies. Danaher Corporation was founded in 1969 and is headquartered in Washington, the District of Columbia.

Sources: Company filings and publicly available information.
  1. This material has been prepared solely for informative purposes as of its stated date and is not a solicitation, or an offer, to buy or sell any security. It does not purport to be a complete description of the securities, markets or developments referred to in the material. Information included in the material was obtained from external sources which we consider reliable, but we have not independently verified such information and do not guarantee that it is accurate or complete. Such information is believed to be accurate on the date of issuance of the material. No subsequent publication or distribution of this material shall mean or imply that any such information or opinion remains current at any time after the stated date of the material. We do not undertake to advise you of any changes in any such information or opinion. Additional information is available upon request.